EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

125I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy

Xuemin Di, Zhen Gao, Huimin Yu, Xiaoli Liu, Jinxin Zhao, Juan Wang, Hongtao Zhang

Radiation Oncology · 2024

DOI: 10.1186/s13014-024-02454-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Oncology, 2024. Verfasst von Xuemin Di und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, Hebei, 050051, China. Hauptthemen laut MEDLINE: Brachytherapy, Uterine Cervical Neoplasms, Iodine Radioisotopes, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the efficacy of 125 I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy, and to analyze the clinical influential factors.

Methods

Between June 2015 and April 2022, 32 patients with 41 lesions were treated with 125 I seed brachytherapy. The seeds were implanted under the guidance of CT and/or 3D-printed template images at a median dose of 100 Gy (range, 80–120 Gy), and the local control rate (LCR) and survival rates were calculated. We used multivariate logistic regression to identify prognosis predictors, and receiver operating characteristic (ROC) curve analysis to determine the optimal cut-off values.

Results

The median follow-up was 48.52 months (range, 4–86 months), and the 6-, 12-, and 24-month LCR was 88.0%, 63.2%, and 42.1%, respectively. The 1- and 2-year survival rates were 36% and 33%, respectively, and the median survival time was 13.26 months. No significant adverse events occurred. Multivariate regression analysis showed that tumor diameter, tumor stage, and LCR were independent factors influencing survival. ROC curve analysis showed that the area under the curve for tumor diameter and D90 were 0.765 and 0.542, respectively, with cut-off values of 5.3 cm and 108.5 Gy.

Conclusions

The present findings indicate that 125 I seed brachytherapy is feasible for treating non-central pelvic recurrence of cervical cancer after external beam radiotherapy. Further, tumor diameter < 5.3 cm and immediate postoperative D90 > 108.5 Gy were associated with better efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyUterine Cervical NeoplasmsIodine RadioisotopesNeoplasm Recurrence, LocalHumansFemaleMiddle AgedAgedAdultSurvival RateRetrospective StudiesPelvic NeoplasmsPrognosisRadiotherapy DosageFollow-Up StudiesAged, 80 and over

Stichwörter der Autor:innen

BrachytherapyExternal Beam RadiotherapyLocoregionalNon-central pelvic recurrence of Cervical CancerPelvic recurrence

Substanzen

Iodine RadioisotopesIodine-125

Autor:innen und Institutionen

  • Department of Oncology, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, Hebei, 050051, China.
  • Department of Oncology, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, Hebei, 050051, China. hongtaozhangmd@163.com.

Zitieren

APA

Di, X., Gao, Z., Yu, H., Liu, X., Zhao, J., Wang, J., & Zhang, H. (2024). 125I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy. Radiation Oncology. https://doi.org/10.1186/s13014-024-02454-1

Vancouver

Di X, Gao Z, Yu H, Liu X, Zhao J, Wang J, et al. 125I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy. Radiation Oncology. 2024. doi:10.1186/s13014-024-02454-1

BibTeX
@article{Di2024,
  author = {Di, Xuemin and Gao, Zhen and Yu, Huimin and Liu, Xiaoli and Zhao, Jinxin and Wang, Juan and Zhang, Hongtao},
  title = {125I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy},
  journal = {Radiation Oncology},
  year = {2024},
  doi = {10.1186/s13014-024-02454-1}
}
Kostenlos starten →